Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using eisai hyperbilirubinemic rats

Pharmaceutical Research

Volumn 20, Issue 1, 2003, Pages 31-37

  Chen, Cuiping ^a   Scott, Dennis ^a   Hanson, Elizabeth ^a   Franco, Judy ^a   Berryman, Edwin ^a   Volberg, Marlo ^a   Liu, Xingrong ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Absorption; Biliary excretion; Eisai hyperbilirubinemic rats; Multidrug resistance associated protein 2

Indexed keywords

FUROSEMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 2; PROBENECID;

ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; HYPERBILIRUBINEMIA; INTESTINE ABSORPTION; MALE; MASS SPECTROMETRY; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; RAT;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILIARY TRACT; CARRIER PROTEINS; FUROSEMIDE; HYPERBILIRUBINEMIA; INTESTINAL ABSORPTION; MALE; METHOTREXATE; PROBENECID; RATS; RATS, MUTANT STRAINS; RATS, SPRAGUE-DAWLEY;

EID: 0037260573     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022238506509     Document Type: Article

References (27)

1. P. Borst, R. Evers, M. Kool, and J. Wijnholds. The multidrug resistance protein family. Biochim. Biophys. Acta 1461:347-357 (1999).
2. J. Konig, A. T. Nies, Y. Cui, I. Leier, and D. Keppler. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461:377-394 (1999).
3. A. Ayrton and P. Morgan. The role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 3:469-497 (2001).
4. D. Keppler and J. Konig. Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 20:265-272 (2000).
5. E. Bakos, R. Evers, E. Sinko, A. Varadi, P. Borst, and B. Sarkadi. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 57:760-768 (2000).
6. M. Masuda, Y. I'izuka, M. Yamazaki, R. Nishgaki, Y. Kato, K. Ni'inuma, H. Suzuki, and Y. Sugiyama. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res. 57:3506-3510 (1997).
7. X. Y. Chu, Y. Kato, and Y. Sugiyama. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res. 57:1934-1938 (1997).
8. - rats. J. Pharmacol. Exp. Ther. 295:512-518 (2000).
9. O. Takenaka, T. Horie, H. Suzuki, and Y. Sugiyama. Different biliary excretion systems for glucuronide and sulfate of a model compound: study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 274:1362-1369 (1995).
10. Y. Kato, T. Igarashi, and Y. Sugiyama. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. Drug Metab. Disp. 28:1146-1148 (2000).
11. P. L. M. Jansen, W. H. M. Peter, and W. H. Lamers. Hereditary chronic conjugated hyperbilirubinaemia in mutant rats caused by defective hepatic anion transport. Hepatology 5:573-579 (1985).
12. T. Mimaki, T. Nozaki, O. Tagaya, S. Hosokawa, T. Nakura, H. Mori, S. Kondou, Y. Matsubara, and T. Ougoh. The character of a new mutant in rats with hyperbilirubinuria syndrome. Congen. Anom. 26:250-251 (1986).
13. K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama. Molecular cloning of canaliculiar multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 272:G16-G22 (1997).
14. H. Ishizuka, K. Konno, H. Naganuma, K. Sasahara, Y. Kawahara, K. Ninuma, H. Suzuki, and Y. Sugiyama. Temocaprilat, a novel angiotensin-converting enzyme inhibitor, is excreted in bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J. Pharmacol. Exp. Ther. 280:1304-1311 (1997).
15. M. Yamazaki, S. Akiyama, K. Ni'inuma, R. Nishigaki, and Y. Sugiyama. Biliary excretion of pravastatin in rats: contribution of the excretion pathways mediated by the canalicular multispecific organic anion transporter (cMOAT). Drug Metab. Disp. 25:1123-1129 (1997).
16. A. Morikawa, Y. Goto, H. Suzuki, T. Hirohashi, and Y. Sugiyama. Biliary excretion of 17β-estradiol 17β-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm. Res. 17:546-552 (2000).
17. A. D. Mottino, T. Hoffman, L. Jennes, and M. Vore. Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J. Pharmacol. Exp. Ther. 293:717-723 (2000).
18. Y. Gotoh, H. Suzuki, S. Kinoshita, T. Hirohashi, Y. Kato, and Y. Sugiyama. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J. Pharmacol. Exp. Ther. 292:433-439 (2000).
19. C. G. Dietrich, D. R. D. Waart, R. Ottenhoff, and I. G. Schoots. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-pheylimidazo[4,5-b]pyridine in Mrp-2-deficient rats. Mol. Pharmacol. 59:974-980 (2001).
20. 14-furosemide in the rat. Xenobiotica 21:725-736 (1991).
21. J. H. Park, W. I. Lee, W. H. Yoon, Y. D. Park, J. S. Lee, and M. G. Lee. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm. Drug Disp. 19:357-364 (1998).
22. W. D. Conway and S. Melethil. Excretion of probenecid and its metabolites in bile and urine of rats. J. Pharm. Sci. 63:1551-1554 (1974).
23. B. M. Emanuelsson, B. Beermann, and L. K. Paalzow. Nonlinear elimination and protein binding of probenecid. Eur. J. Clin. Pharmacol. 32:395-401 (1987).
24. T. Kuroda, K. Namba, T. Torimaru, K. Kawashima, and M. Hayashi. Species difference in oral bioavailability of methotrexate between rats and monkeys. Biol. Pharm. Bull. 23:334-338 (2000).
25. K. W. Ward, J. W. Proksch, M. A. Levy, and B. R. Smith. Development of an in vitro preclinical screen model to estimate absorption and bioavailability of xenobiotics. Drug Metab. Disp. 28:82-88 (2001).
26. K. Ueda, K. Kato, K. Komatsu, and Y. Sugiyama. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. J. Pharmacol. Exp. Ther 297:1036-1043 (2001)
27. H. Sun, D. W. Miller, and W. F. Elmquist. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm. Res. 18:1542-1549 (2001).